Crystal of beta-nicotinamide-adenine-dinucleotide and process for preparing the same

Novel highly pure and stable crystals of .beta.-nicotinamide-adenine-dinucleotide tetrahydrate (NAD) which is triclinic system and has a space group of P1 or P1 and lattice constants: a=8.861 .ANG., b=11.181 .ANG., c=8.630 .ANG., .alpha.=90.82.degree., .beta.=103.40.degree. and .gamma.=109.71.degree.. The crystalline NAD is prepared by cooling a 20 to 60 w/v % aqueous solution of amorphous NAD, which has preferably been treated with a porous weakly basic anion exchange resin to remove impurities, at a temperature of 0.degree. to 20.degree. C. When the crystalline NAD is added to the aqueous solution as seeds, the desired high pure crystalline NAD is prepared without conducting the treatment of amorphous NAD with the porous weakly basic anion exchange resin. A high pure amorphous NAD is obtained from the crystalline NAD by dissolving the crystalline NAD in water and subjecting the aqueous solution to freeze drying or precipitation with a solvent.

BACKGROUND OF THE INVENTION 
The present invention relates to crystals of 
.beta.-nicotinamide-adenine-dinucleotide of free acid type and a process 
for preparing the crystals. 
.beta.-Nicotinamide-adenine-dinucleotide (hereinafter referred to as "NAD") 
is present as a coenzyme for various oxidoreductases in almost all of the 
tissues of living bodies, and has a very important role in energy 
metabolism, biosynthesis, etc. in a living body. Therefore, in recent 
years, the demand for NAD has increased not only as reagents for research 
on biochemistry and physiology, but also as chemicals indispensable to 
clinical diagnosis as a factor of measurement in enzymatic analysis upon 
measuring enzyme activity and concentration of a substrate. 
Hitherto, NAD has been obtained in solid form by isolating NAD from yeast 
extract or a cultured broth of a microorganism by various methods of the 
isolation such as ion exchange chromatography and subjecting the obtained 
solution of NAD to a method such as freeze drying or precipitaion with an 
organic solvent followed by separation and drying of the precipitate. The 
thus obtained solid NAD is amorphous, and is very hygroscopic and 
deliquesces in air. In many cases, such an amorphous NAD still contains a 
trace amount of impurities. Also, the amorphous NAD is unstable, and 
lowering of the purity due to thermal decomposition during storage and 
transportation is unavoidable. It is known that a competitive inhibitor of 
an enzyme is present in the thermal decomposition fragments and a trace 
amount of other impurities. Therefore, it is well known that the use of 
such a NAD of low purity in the enzymatic analysis gives only results 
having a large error, for instance, from Dalziel, J. Biol. Chem., Vol. 
238, 1538(1963). 
Crystallization of NAD of free acid type has been reported by A. D. Winer 
in J. Biol. Chem., Vol. 239, PC3598(1964). However, this process uses a 
large amount of a solvent and moreover requires a very low temperature, 
i.e. -15.degree. C. The standard parameters for this process are 
indefinite and there is no reproducibility. Also, the disclosed crystals 
are crystals of NAD trihydrate which are long thin needles or flat prisms, 
and it is reported that the crystalline NAD changes into the amorphous 
form by the change in surrounding humidity and the stability is bad. 
Further, the process has the disadvantage that the purified product 
obtained by the use of a solvent contains a slight amount of the 
unseparable solvent. Also, the use of a large amount of a solvent is not 
economical, and the process has no practical importance as an industrial 
process. 
Crystals of a metal salt of NAD such as the lithium salt are also known. 
However, when NAD free acid is required, the metal salt must be treated 
again with an ion exchange resin, and accordingly the purification of 
amorphous NAD by this process is disadvantageous in increase of the 
process steps. 
It is an object of the present invention to provide novel crystals of NAD 
of free acid type. 
A further object of the invention is to provide crystalline NAD having a 
high purity and a high stability. 
A still further object of the invention is to provide amorphous NAD having 
a high purity. 
Another object of the invention is to provide a process for preparing NAD 
having a high purity in a simple manner in a high yield. 
These and other objects of the present invention will become apparent from 
the description hereinafter. 
SUMMARY OF THE INVENTION 
In accordance with the present invention, there is provided a crystalline 
.beta.-nicotinamide-adenine-dinucleotide tetrahydrate which is triclinic 
system and has a space group of Pl or Pl and lattice constants: a=8.861 
.ANG., b=11.181 .ANG., c=8.630 .ANG., .alpha.=90.82.degree., 
.beta.=103,40.degree. and .gamma.=109.71.degree.. 
The crystals are prepared by cooling a 20 to 60 w/v % aqueous solution of 
amorphous NAD at a temperature of 0.degree. to 20.degree. C. to 
crystallize NAD tetrahydrate. The process is very simple and the NAD 
crystals having a high purity and an excellent stability are economically 
obtained in high yields. The crystals of the invention is very useful for 
providing amorphous NAD having a high purity.

DETAILED DESCRIPTION 
Amorphous NAD which has been prepared by a generally known method such as 
precipitation from an aqueous solution of NAD with an organic solvent 
followed by separation and drying or freeze drying of the aqueous 
solution, is employed as a starting material for preparing the crystalline 
NAD of the present invention. In many cases, such as amorphous NAD 
contains impurities. Impurities can be removed by any known methods. In 
the present invention, it is desirable that the enzymatic purity of the 
amorphous NAD is at least 90%, since NAD crystallizes out with ease and 
also the yield of crystallization increases. Preferably, the amorphous NAD 
is purified by treating an aqueous solution of amorphous NAD with a porous 
weakly basic anion exchange resin converted into acetate form, carbonate 
form, phosphate form, hydrochloride form or OH form (free base form). In a 
preferable embodiment, the amorphous NAD is purified by passing an aqueous 
solution of amorphous NAD through a column of a high porous weakly basic 
anion exchange resin converted into acetate form such as Diaion WA30 (made 
by Mitsubishi Chemical Industries Ltd.), Amberlite IRA-93 (made by Rohm & 
Haas Co.), Dowex HWA-1 (made by Dow Chemical Co.), or Duolite A-368PR 
(made by Diamond Shamrock Corp.). Since NAD is also adsorbed by this anion 
exchange resin, the anion exchange resin is preferably employed in the 
smallest amount necessary for removing impurities. NAD crystals of the 
present invention obtained from an aqueous solution of amorphous NAD 
purified by this method are very pure and are excellent as seeds for 
crystallizing NAD. 
Upon crystallization, it is necessary for producing the crystals of the 
invention that the concentration of an aqueous solution of NAD is from 20 
to 60 w/v %, preferably 40 to 50 w/v %. When the concentration is less 
than 20 w/v %, crystallization is hard to occur and the yield is also very 
low. When the concentration is more than 60 w/v %, the aqueous solution is 
difficult to handle due to high viscosity. The concentration is adjusted 
within the above range before or after the purification of NAD. The 
aqueous solution is cooled at a temperature of 0.degree. to 20.degree. C., 
preferably 2.degree. to 8.degree. C. for crystallization. Crystallization 
completes in 1 or 2 days when the aqueous solution is allowed to stand, 
and in several hours when the aqueous solution is gently stirred to 
accelerate the growth of crystals. 
It is effective to employ, upon crystallization, separately prepared NAD 
crystals as seeds. In case of conducting the crystallization by employing 
seeds, the desired crystalline NAD can be obtained by cooling a 20 to 60 
w/v % aqueous solution of NAD at a temperature of 0.degree. to 20.degree. 
C. without subjecting NAD to the purification by means of an ion exchange 
resin such as the above-mentioned high porous ion exchange resin. Although 
it is possible to obtain the desired crystals even if the enzymatic purity 
of the amorphous NAD used is low, preferably the amorphous NAD having an 
enzymatic purity of not less than 90%, especially not less than 93%, is 
employed, since the crystallization occurs with ease and also the yield 
can be increased. 
The produced crystals are separated in a usual manner. According to the 
present invention, the crystals are obtained in a yield of about 90% or 
more. The NAD crystals of the present invention have the following 
properties. 
Analysis for C.sub.21 H.sub.27 O.sub.14 N.sub.7 P.sub.2.4H.sub.2 O (M. W.: 
735.48): Calcd. (%): C 34.29, H 4.80, N 13.33, P 8.42. Found (%): C 34.57, 
H 4.73, N 13.28, P 8.40. 
Water content by Karl Fischer's method: 9.4% (Theoretical value: 9.8%) 
Crystal system: triclinic system 
Space group: Pl or Pl 
Lattice constant: 
a=8.861 .ANG. 
b=11.181 .ANG. 
c=8.630 .ANG. 
.alpha.=90.82.degree. 
.beta.=103.40.degree. 
.gamma.=109.71.degree. 
V=779.01 .ANG..sup.3 
Density: Found .rho.=1.550. Calcd. .rho.=1.567 (calculated as Z=1). A 
photograph of the crystals of the present invention observed by a 
microscope of 100 magnifications is shown in FIG. 1. Also, X-ray 
diffraction spectrum and infrared spectrum of the crystals of the present 
invention are shown in FIG. 3 and FIG. 4, respectively. FIG. 2 is an X-ray 
diffraction spectrum of amorphous NAD. 
The thus obtained crystalline NAD of free acid type has no defects of a 
conventional amorphous NAD. The crystalline NAD of the present invention 
is crystals having 4 crystal waters, and is stable and is not hygroscopic 
and has a flowability. It is also excellent in storage stability, and has 
no odor and a beautiful appearance, and accordingly is of great commercial 
value. The crystals of the present invention do not lose the crystal 
framework, even if compulsorily dehydrated, and return easily to the 
original crystals by giving water. With respect to the stability of the 
crystals of the invention, the lowering of the enzymatic purity does not 
occur at all, even if the crystals are maintained, for instance, at 
37.degree. C. for 24 days, though amorphous NAD shows lowering of the 
purity by about 10% under the same condition and lowers its purity with 
the lapse of time. According to the enzymatic analysis, the crystalline 
NAD of the present invention is 100% pure as .beta.-NAD, and inclusion of 
enzyme inhibitors such as LDH (lactate dehydrogenase) inhibitor has not 
been observed. According to the liquid chromatography, a commercially 
available .beta.-NAD contains a trace amount of impurities, especially 
.alpha.-NAD and ADP-ribose (adenosine 5-diphosphateribose), but these 
impurities have not been detected from the crystalline NAD of the present 
invention. FIG. 5 shows a high performance liquid chromatogram of a 
commercially available amorphous NAD which has been purified by 
precipitating NAD with addition of methanol from an aqueous solution of 
amorphous NAD treated with an ion exchange resin, and FIG. 6 shows a high 
performance liquid chromatogram of the crystalline NAD of the present 
invention. In FIG. 5, A is a peak of AMP (adenosine 5-monophosphate) and B 
is a peak of ADP-ribose. AMP and ADP-ribose are detected in the commercial 
preparation, but they are not detected in the crystalline NAD of the 
present invention. The conditions of the high performance liquid 
chromotography are as follows: 
Column: .mu.-Bondapak NH.sub.2 (4 mm. in inner diameter and 30 cm. in 
length). 
Solvent: 0.1M NH.sub.4 H.sub.2 PO.sub.4 (pH 3.5). 
Flow rate: 2.0 ml./min. 
Chart speed: 1.0 cm./min. 
Detection: UV 254 nm., 0.5 AUFS. 
NAD sample concentration: 1.0 mg./ml. 
The crystalline NAD of the present invention is very pure, i.e. about 100% 
pure, and does not contain contaminants which cause errors in enzymatic 
analysis. Also, it is stable, and upon storage or transportation, there is 
no necessity of maintaining the temperature low as required for 
conventional NAD. Further, the process of the present invention has the 
advantage on industrial production that a purification procedure as 
conducted in a conventional process in which addition of a large amount of 
a solvent is repeated is not necessary and the crystals can be obtained 
from an aqueous solution of NAD without using a solvent. 
When a high pure amorphous NAD is desired, it can be easily obtained by 
dissolving the crystalline NAD of the present invention in water, and then 
subjecting the resulting aqueous solution to freeze drying or adding the 
aqueous solution to an alcohol such as methanol to precipitate NAD. For 
instance, the crystals of the present invention are dissolved in a hot 
water to prepare a 10 to 50 w/v % aqueous solution of NAD, and the aqueous 
solution is immediately cooled to room temperature, e.g. 18.degree. to 
25.degree. C. in order to avoid the thermal decomposition of NAD. The 
aqueous solution is then lyophilized, or is poured to an alcohol with 
agitation to precipitate NAD which is separated and dried. It is apparent 
from the foregoing description as to crystalline NAD and a process for the 
preparation thereof that this process for the preparation of amorphous NAD 
using the crystals of the invention is very superior to a conventional 
process in that high pure products can be obtained by a simple procedure. 
Thus, the present invention also provides a process for the purification 
of amorphous NAD. 
The present invention is more specifically described and explained by means 
of the following Examples. 
EXAMPLE 1 
A NAD-containing extract obtained from cells of a microorganism was 
purified by ion exchange chromatography, and the obtained aqueous solution 
of NAD was added to methanol of 9 times the volume of the aqueous solution 
to precipitate NAD. The precipitate was filtered, washed with a slight 
amount of methanol, and dried under reduced pressure to give a powder of 
purified amorphous NAD. The enzymatic purity of the powder was 92%. The 
thus obtained amorphous NAD powder was employed as the starting material. 
An aqueous solution of 100 g. of the powder dissolved in 200 ml. of water 
was passed through a column of 1.5 cm. in inner diameter packed with 20 
ml. of a high porous weakly basic anion exchange resin converted into 
acetate form (commercially available under the commercial name "Diaion 
WA30" made by Mitsubishi Chemical Industries Ltd.) from the top of the 
column at a space velocity of 1 hr..sup.-1 Subsequently, 40 ml. of 
deionized water was passed through the column, and 220 ml. of the 
NAD-containing fraction in the eluate was collected. 
The fraction was cooled to 5.degree. and allowed to stand at that 
temperature. After 16 hours, crystals which served as crystal nucleus 
began to appear on the bottom of a vessel, and subsequently the fraction 
was gently stirred at 5.degree. C. for 5 hours to produce crystals. The 
crystals were filtered under suction, washed with a slight amount of water 
and dried under vacuum to give 90 g. of crystalline NAD tetrahydrate. The 
enzymatic purity of the crystals was 100% on dry basis. 
EXAMPLE 2 
A NAD-containing extract obtained from cells of a microorganism was 
purified by ion exchange chromatography, and the eluate was lyophilized to 
give purified amorphous NAD, the enzymatic purity of which was 91%. 
The procedure of Example 1 was repeated except that an aqueous solution of 
500 g. of the above amorphous NAD dissolved in 1 liter of water and 
Amberlite IRA-93 (made by Rohm & Haas Co.) as an ion exchange resin were 
employed, to give 455 g. of crystalline NAD tetrahydrate which was 100% 
enzymatically pure. 
EXAMPLE 3 
In 200 ml. of water was dissolved 100 g. of an amorphous NAD powder 
(enzymatic purity: 93.5%) prepared in the same manner as in Example 1. To 
the obtained aqueous solution was added 5 mg. of crystalline NAD obtained 
in Example 1 as seeds for crystallization. The aqueous solution was then 
stirred at 5.degree. C. for 6 hours, and the resulting crystals were 
separated and dried. The yield of crystalline NAD was 91.5 g., and the 
enzymatic purity was 99.8%. 
EXAMPLE 4 
The procedure of Example 3 was repeated except that there was employed a 50 
w/v % aqueous solution of amorphous NAD obtained by dissolving in water 39 
g. of amorphous NAD having an enzymatic purity of 92%, to give 35 g. of 
crystalline NAD. The thus obtained crystals contained 9.4% by weight of 
water and 90.5% by weight of NAD. 
In 100 ml. of distilled water was dissolved 35 g. of the crystals at 
46.degree. C. Immediately after the dissolution, the aqueous solution was 
cooled to 20.degree. C. The aqueous solution was then filtered through a 
membrane filter (commercially available under the commercial name 
"Millipore Filter" made by Millipore Corporation) having a pore size of 
0.22 .mu.m., and was lyophilized to give 32 g. of a high pure amorphous 
NAD. The thus obtained amorphous NAD powder contained 2.8% by weight of 
water and 97% by weight of NAD. The enzymatic purity of the powder was 
99.8% on dry basis. 
EXAMPLE 5 
In 200 ml. of distilled water of 46.degree. C. was dissolved 26 g. of the 
crystalline NAD obtained in Example 4, and immediately after the 
dissolution, the aqueous solution was cooled to 20.degree. C. The aqueous 
solution was then filtered through a membrane filter having a pore size of 
0.22 .mu.m., and added to 1.8 liters of methanol with stirring. The 
resulting precipitate was collected by a decanter, washed with a slight 
amount of methanol and dried under reduced pressure to give 23 g. of high 
pure amorphous NAD. The thus obtained amorphous NAD powder contained 95.0% 
by weight of NAD and 3.0% by weight of water. The enzymatic purity of the 
powder was 97.9% on dry basis.